Why the study?
Guidelines recommend early dual antiplatelet therapy for NSTEACS, but observational studies suggest this rarely occurs, leaving site variation and associated clinical outcomes unclear.
Does early dual antiplatelet therapy (DAPT) reduce recurrent MI and mortality in patients undergoing angiography for non-ST elevation acute coronary syndromes?
Observational (n=45,569)
Yes
Does early dual antiplatelet therapy (DAPT) reduce recurrent MI and mortality in patients undergoing angiography for non-ST elevation acute coronary syndromes?
Answers are grounded in this paper and cite their sources.
Early DAPT in NSTEACS patients undergoing angiography does not improve clinical outcomes but delays surgical revascularization, challenging current guideline recommendations for early administration.
OBJECTIVE: Current guidelines recommend that patients with non-ST elevation acute coronary syndromes (NSTEACS) receive dual antiplatelet therapy (DAPT) early in hospitalisations. However, observational studies suggest that this rarely occurs. We evaluated site-specific variation and clinical outcomes associated with early DAPT among patients undergoing angiography for NSTEACS. METHODS: In this observational analysis, we identified patients undergoing angiography for NSTEACS in Veterans Affairs hospitals from 2008 to 2016 and assessed characteristics and site variation associated with early DAPT (administration <24 hours of admission). Using propensity matching, we compared time to revascularisation, recurrent myocardial infarction (MI) and mortality between those receiving early DAPT and those not receiving early DAPT (administration ≥24 hours). RESULTS: Of 45 569 patients undergoing angiography for NSTEACS, 15 084 (33%) received early DAPT. Early DAPT was more frequent in patients with non-ST elevation MI, prior surgical revascularisation and among patients undergoing revascularisation. There was a greater than twofold difference in early DAPT across sites, independent of patient characteristics (median OR 2.43, 95% CI 2.28 to 2.55). There was no difference in time topercutaneous coronary intervention (PCI) between groups, but a significant delay to surgical revascularisation with early DAPT (median 4 vs 3 days, p<0.001) without reduction in hazard of death or MI (HR 1.08, 95% CI 1.00 to 1.16) and similar results demonstrated in the subgroup of patients undergoing revascularisation (HR 1.02, 95% CI 0.91 to 1.13). CONCLUSION: Among NSTEACS patients undergoing coronary angiography, early DAPT was not associated with improvement of outcomes but was associated with delays in surgical revascularisation.
No takes yet. Share an insight, caveat, or question.
Valle et al. (2019) conducted an observational in Non-ST elevation acute coronary syndromes (NSTEACS) (n=45,569). Early dual antiplatelet therapy (DAPT) (<24 hours of admission) vs. No early DAPT (administration ≥24 hours) was evaluated on Death or recurrent myocardial infarction (HR 1.08, 95% CI 1.00 to 1.16).
Synapse has enriched 10 related papers. Consider them for comparative context: